Novavax's protein-based vaccine will be available soon after regulators granted emergency authorization to the Maryland-based company for the product.
FDA officials said that animal testing data supported the decision.
"Today's authorization provides an additional COVID-19 vaccine option that meets the FDA's standards for safety, effectiveness and manufacturing quality needed to support emergency use authorization," Dr. Peter Marks, who directs the FDA's Center for Biologics Evaluation and Research, said in an Aug. 30 statement.
The FDA cleared vaccines from Moderna and Pfizer that are built on messenger ribonucleic acid (mRNA) technology earlier in the month....<<<Read More>>>....
